Oryzon Genomics
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.
1 past transactions
Crystax
Acquisition in 2009
Crystax Pharmaceuticals is a prominent structure-based drug discovery company focused on identifying and developing innovative therapeutic molecules, particularly for cancer treatment. The company employs a range of structural and biophysical techniques, including X-ray Crystallography, NMR, Fragment Screening, and Hit Optimization, to enhance the drug discovery process. By integrating these advanced methodologies, Crystax aims to accelerate the development of high-quality lead compounds, ultimately improving the efficacy and safety of new medications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.